Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.54 |
| ▸ | CSF1R | P07333 | 8/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.51 |
| ▸ | MET | P08581 | 3/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | AXL | P30530 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL573865 | 0.94 | AXL (0.55) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL573555 | 0.87 | AXL (0.56) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL573744 | 0.87 | KDR (0.60) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL574169 | 0.86 | CSF1R (0.53) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL573841 | 0.86 | AXL (0.55) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL574521 | 0.84 | AXL (0.46) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL574339 | 0.84 | KDR (0.56) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL573891 | 0.84 | AXL (0.47) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL573554 | 0.84 | KDR (0.59) | KDRCSF1RPDGFRAPDGFRBMET | |
| SCHEMBL574850 | 0.83 | KDR (0.45) | KDRCSF1RPDGFRAPDGFRBMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | KDR 2434/4885CSF1R 1244/4885PDGFRA 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.